Omeros

Yahoo Finance • 15 days ago

Omeros Corp (OMER) Q4 2025 Earnings Call Highlights: A Turnaround with Strategic Deals and FDA ...

This article first appeared on GuruFocus. Net Income (Q4 2025): $86.5 million or $1.22 per share. Net Loss (Q3 2025): $30.9 million or $0.47 per share. Net Gain from Zaltnibart Transaction: $237.6 million. Non-GAAP Adjusted Net Income (Q4... Full story

Yahoo Finance • 15 days ago

Omeros Non-GAAP EPS of $3.14 beats by $2.78

* Omeros press release [https://seekingalpha.com/pr/20458005-omeros-corporation-reports-fourth-quarter-and-year-end-2025-financial-results] (OMER [https://seekingalpha.com/symbol/OMER]): Q4 Non-GAAP EPS of $3.14 beats by $2.78. * At De... Full story

Yahoo Finance • 15 days ago

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

– Conference Call Today at 4:30 p.m. ET SEATTLE, March 31, 2026--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended Dece... Full story

Yahoo Finance • 15 days ago

After-Hours Earnings Report for March 31, 2026 : NKE, PVH, RH, NCNO, OMER, PLAY, BYND, DUOT, REKR, DGXX, BHST, SPWH

The following companies are expected to report earnings after hours on 03/31/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Nike, Inc. (NKE)is reporting for the quarter ending February 28, 2026. The sh... Full story

Yahoo Finance • 17 days ago

Earnings week ahead: NKE, TLRY, SPCE, BYND, NNDM, CAG, and more

[Nest of Eggs] LindaJoHeilman As the calendar turns from March to April, a holiday-shortened week still delivers a diverse set of earnings with the potential to offer fresh directional cues. Consumer and brand momentum will be in focus w... Full story

Yahoo Finance • 4 months ago

Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA

Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a frequent life-threatening condition that can oc... Full story

Yahoo Finance • 4 months ago

FDA Approves Omeros' Yartemlea, First Approved Drug For Rare Post-Transplant TA-TMA

(RTTNews) - Omeros Corp. (OMER) said Thursday that the U.S. Food and Drug Administration has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ra... Full story

Yahoo Finance • 4 months ago

Wednesday Sector Leaders: Drugs, Biotechnology Stocks

In trading on Wednesday, drugs shares were relative leaders, up on the day by about 1.6%. Leading the group were shares of Omeros, up about 84.5% and shares of Dynavax Technologies up about 38.6% on the day. Also showing relative strengt... Full story

Yahoo Finance • 4 months ago

Sector Update: Health Care Stocks Rise Wednesday Afternoon

Health care stocks were rising in recent early Wednesday afternoon trading, with the NYSE Health Car PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

OMER Surges 81% On FDA Approval Of Yartemlea For Transplant-Related TA-TMA

(RTTNews) - Omeros Corporation (OMER) jumped 81.14%, closing at $15.85, up $7.10, after the U.S. FDA approved Yartemlea (narsoplimab-wuug) for the treatment of transplant-associated thrombotic microangiopathy (TA-TMA), a serious complicati... Full story

Yahoo Finance • 4 months ago

Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz

Omeros Corporation (NASDAQ:OMER) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz Latest reports show that Omeros Corporation (NASDAQ:OMER) has closed a deal... Full story

Yahoo Finance • 4 months ago

Do You Believe Omeros Corporation’s (OMER) New Monoclonal Antibody Has Strong Chances of Approval?

Jacob Fund is a mutual fund company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The latest quarter showed continued market recovery, with major equity indexes reaching new all-time highs.... Full story

Yahoo Finance • 4 months ago

Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart

[New Nordisk] hapabapa * Omeros (OMER [https://seekingalpha.com/symbol/OMER]) and Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) have closed a deal worth up to $2.1B for the former's phase 2 asset zaltenibart, in development f... Full story

Yahoo Finance • 4 months ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

SEATTLE, December 01, 2025--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Za... Full story

Yahoo Finance • 5 months ago

Omeros Awaits FDA Decision On Lead Drug Candidate Narsoplimab Next Month

(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the third quarter ended September 30, 2025, a... Full story

Yahoo Finance • 5 months ago

Applied Therapeutics, Omeros, And Others Post Sharp Moves After Market Close

(RTTNews) - Several companies posted notable moves in after-hours trading on Thursday, driven by earnings announcements and regulatory updates. Shares of Milestone Scientific Inc. (MLSS) rose sharply in extended trading, climbing to $0.52... Full story

Yahoo Finance • 5 months ago

After-Hours Earnings Report for November 13, 2025 : AMAT, BAP, STN, GLOB, TMC, TRVI, PGEN, BZH, OMER, TBN, TOI, AIRJ

The following companies are expected to report earnings after hours on 11/13/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Applied Materials, Inc. (AMAT)is reporting for the quarter ending October 31,... Full story

Yahoo Finance • 6 months ago

Is Omeros Corporation (OMER) One of the Hot Stocks to Buy with Huge Upside Potential?

Omeros Corporation (NASDAQ:OMER) is one of the hot stocks to buy with huge upside potential. On October 15, H.C. Wainwright raised the firm’s price target on Omeros to $20 from $9 and kept a Buy rating on the shares. This sentiment followe... Full story

Yahoo Finance • 6 months ago

J.P. Morgan Maintains a Buy on Novo Nordisk (NVO)

Novo Nordisk A/S (NYSE:NVO) is one of the best long term low volatility stocks to buy right now. J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk A/S (NYSE:NVO) in a report released on October 17, setting a price... Full story

Yahoo Finance • 6 months ago

Omeros Sells Exclusive Global Rights for Drug Zaltenibart to Novo Nordisk

Omeros Corporation (NASDAQ:OMER) is one of the Reddit stocks that will go to the moon. On October 15, Omeros Corporation and Novo Nordisk (NYSE:NVO) announced a definitive asset purchase and license agreement for the clinical-stage candida... Full story